Prevalence of Transmitted HIV Drug Resistance in Iran between 2010 and 2011

D Popp, 2002, First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world, AIDS, 16, 676, 10.1097/00002030-200203080-00025

DE Bennett, 2008, Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment, Antivir Ther, 13, 25, 10.1177/135965350801302S04

National AIDS Committee Secretariat,Ministry of Health and Medical Education.Islamic Repoblic of Iran (2008) Progress Report on Monitoring of United Nations General Assembly Special Session (UNGASS) on HIV and AIDS.

Ministry of Health and Medical Education (MHME), Iran, (March 2012) AIDS/HIV surveillance report, MHME, Tehran.

M Vazirian, 2005, Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: a cross-sectional study, Harm Reduct J, 2, 19, 10.1186/1477-7517-2-19

S Zamani, 2005, Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran, AIDS, 19, 709, 10.1097/01.aids.0000166094.24069.72

National AIDS Committee Secretariat, Ministry of Health and Medical Education.(updated March 2012) Islamic Republic of Iran Progress Report on Monitoring of the United Nations General Assembly Special Session (UNGASS) on HIV and AIDS.

S Bertagnolio, 2008, World Health Organization/HIVResNet Drug Resistance Laboratory Strategy, Antivir Ther, 13, 49, 10.1177/135965350801302S05

W Sugiura, 1999, Prevalence of drug resistance-related mutations among HIV-1s in Japan, Jpn J Infect Dis, 52, 21, 10.7883/yoken.52.21

DE Bennett, 2009, Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update, PLoS One, 4, e4724, 10.1371/journal.pone.0004724

K Tamura, 2011, MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods, Mol Biol Evol, 28, 2731, 10.1093/molbev/msr121

VA Johnson, 2011, 2011 update of the drug resistance mutations in HIV-1, Top Antivir Med, 19, 156

SM Mousavi, 2010, Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study, Arch Virol, 155, 329, 10.1007/s00705-009-0583-6

ZS Soheilli, 2009, Presence of HIV-1 CRF35_AD in Iran, AIDS Res Hum Retroviruses, 25, 123, 10.1089/aid.2008.0199

HR Naderi, 2006, Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran, Infect Agent Cancer, 1, 4, 10.1186/1750-9378-1-4

R Sarrami-Forooshani, 2006, Molecular analysis and phylogenetic characterization of HIV in Iran, J Med Virol, 78, 853, 10.1002/jmv.20634

M Tagliamonte, 2007, HIV type 1 subtype A epidemic in injecting drug user (IDU) communities in Iran, AIDS Res Hum Retroviruses, 23, 1569, 10.1089/aid.2007.0169

M Myatt, 2008, A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings, Antivir Ther, 13, 37, 10.1177/135965350801302S10

AJ Applebaum, 2009, The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients, AIDS Patient Care STDS, 23, 455, 10.1089/apc.2008.0181

A Ammassari, 2004, Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons, Psychosomatics, 45, 394, 10.1176/appi.psy.45.5.394